Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Last Updated: Friday, June 25, 2021
Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30 CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.
Advertisement
News & Literature Highlights